



ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2023 - GENERELL INFORMASJON

Enheten

Organisasjonsnummer: 981 363 019
Organisasjonsform: Aksjeselskap
Foretaksnavn: ABBOTT DIAGNOSTICS TECHNOLOGIES AS
Forretningsadresse: Kjelsåsveien 161
0884 OSLO

Regnskapsår

Årsregnskapets periode: 01.01.2023 - 31.12.2023

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Henriette Bakken
Dato for fastsettelse av årsregnskapet: 27.06.2024

Grunnlag for avgivelse

År 2023: Årsregnskapet er elektronisk innlevert
År 2022: Tall er hentet fra elektronisk innlevert årsregnskap fra 2023

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 08.08.2025



Resultatregnskap

Beløp i: NOK	Note	2023	2022
RESULTATREGNSKAP			
Inntekter			
Salgsinntekt	1	1 380 147 873	1 050 628 960
Annen driftsinntekt	2	0	169 260
Sum inntekter		1 380 147 873	1 050 798 220
Kostnader			
Varekostnad		505 877 210	397 344 558
Lønnskostnad	3,4	169 949 276	147 214 024
Avskrivning	5,6,7	32 889 022	34 082 946
Annen driftskostnad	3,6	677 936 496	384 934 022
Sum kostnader		1 386 652 004	963 575 550
Driftsresultat		-6 504 131	87 222 670
Finansinntekter og finanskostnader			
Inntekt på investering i datterselskap og tilknyttet selskap			
Renteinntekt fra foretak i samme konsern		88 569 102	53 062 449
Annen renteinntekt		437 124	850 176
Annen finansinntekt	8	44 669 116	46 036 231
Sum finansinntekter		133 675 342	99 948 856
Rentekostnad til foretak i samme konsern		248 400	109 388
Annen rentekostnad		132 549	38 733
Annen finanskostnad	9	48 028 232	41 365 091
Sum finanskostnader		48 409 181	41 513 212
Netto finans		85 266 161	58 435 644
Ordinært resultat før skattekostnad		78 762 030	145 658 314
Skattekostnad på ordinært resultat	10	16 480 700	31 224 884
Ordinært resultat etter skattekostnad		62 281 330	114 433 430
Årsresultat		62 281 330	114 433 430



Balanse

Beløp i: NOK	Note	2023	2022
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Varige driftsmidler			
Maskiner og anlegg	5	188 903 860	178 896 058
Skip, rigger, fly og lignende	5	379 248	779 652
Sum varige driftsmidler		189 283 108	179 675 710
Finansielle anleggsmidler			
Lån til foretak i samme konsern	12	919 776 965	2 512 219 785
Sum finansielle anleggsmidler		919 776 965	2 512 219 785
Sum anleggsmidler		1 109 060 073	2 691 895 495
Omløpsmidler			
Varer			
Varer	13	232 574 514	126 379 863
Sum varer		232 574 514	126 379 863
Fordringer			
Kundefordringer	12	211 575	212 575
Andre fordringer	12,14	32 618 328	33 766 404
Utsatt skatt	10	8 908 643	
Konsernfordringer		201 889 135	237 630 341
Sum fordringer		243 627 681	271 609 320
Bankinnskudd, kontanter og lignende			
Bankinnskudd, kontanter og lignende	14	10 860 295	9 737 480
Sum bankinnskudd, kontanter og lignende		10 860 295	9 737 480
Sum omløpsmidler		487 062 490	407 726 663
SUM EIENDELER		1 596 122 563	3 099 622 158



Balanse

Beløp i: NOK	Note	2023	2022
BALANSE - EGENKAPITAL OG GJELD			
Egenkapital			
Innskutt egenkapital			
Aksjekapital	11	2 000 000	2 000 000
Beholdning av egne aksjer	11	1 200 608 665	1 840 095 087
Sum innskutt egenkapital		1 202 608 665	1 842 095 087
Opptjent egenkapital			
Annen egenkapital		62 281 331	521 423 333
Sum opptjent egenkapital		62 281 331	521 423 333
Sum egenkapital		1 264 889 996	2 363 518 420
Gjeld			
Langsiktig gjeld			
Utsatt skatt	10	0	314 888 302
Sum avsetninger for forpliktelser		0	314 888 302
Annen langsiktig gjeld			
Sum langsiktig gjeld		0	314 888 302
Kortsiktig gjeld			
Leverandørgjeld	12	217 788 477	203 036 698
Betalbar skatt	10	12 841 560	113 354 403
Skyldige offentlige avgifter		20 129 503	16 906 168
Annen kortsiktig gjeld	12	80 473 027	87 918 167
Sum kortsiktig gjeld		331 232 567	421 215 436
Sum gjeld		331 232 567	736 103 738
SUM EGENKAPITAL OG GJELD		1 596 122 563	3 099 622 158



Brønnøysundregistrene

ÅRSREGNSKAP FOR REGNSKAPSÅRET 2023 - GENERELL INFORMASJON

Journalnummer: 2024 694223

Enheten

Organisasjonsnummer: 981 363 019
Organisasjonsform: Aksjeselskap
Foretaksnavn: ABBOTT DIAGNOSTICS TECHNOLOGIES AS
Forretningsadresse: Kjelsåsveien 161
0884 OSLO

Regnskapsår

Årsregnskapets periode: 01.01.2023 - 31.12.2023

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av
årsregnskapet til selskapet: Regnskapslovens alminnelige regler
Har utarbeidet 'land-for-land' rapport: Ja

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Henriette Bakken
Dato for fastsettelse av årsregnskapet: 27.06.2024

Grunnlag for avgivelse

År 2023: Årsregnskap er elektronisk innlevert.
År 2022: Tall er hentet fra elektronisk innlevert årsregnskap fra 2023.

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 01.08.2024



Organisasjonsnr: 981 363 019
ABBOTT DIAGNOSTICS TECHNOLOGIES AS

RESULTATREGNSKAP

Beløp i: NOK	Note	2023	2022
RESULTATREGNSKAP			
Inntekter			
Salgsinntekt	1	1 380 147 873	1 050 628 960
Annen driftsinntekt	2	0	169 260
Sum inntekter		1 380 147 873	1 050 798 220
Kostnader			
Varekostnad		505 877 210	397 344 558
Lønnskostnad	3, 4	169 949 276	147 214 024
Avskrivning	5, 6, 7	32 889 022	34 082 946
Annen driftskostnad	3, 6	677 936 496	384 934 022
Sum kostnader		1 386 652 004	963 575 550
Driftsresultat		-6 504 131	87 222 670
Finansinntekter og finanskostnader			
Inntekt på investering i datterselskap og tilknyttet selskap			
Renteinntekt fra foretak i samme konsern		88 569 102	53 062 449
Annen renteinntekt		437 124	850 176
Annen finansinntekt	8	44 669 116	46 036 231
Sum finansinntekter		133 675 342	99 948 856
Rentekostnad til foretak i samme konsern			
		248 400	109 388
Annen rentekostnad		132 549	38 733
Annen finanskostnad	9	48 028 232	41 365 091
Sum finanskostnader		48 409 181	41 513 212
Netto finans		85 266 161	58 435 644
Ordinært resultat før skattekostnad			
Skattekostnad på ordinært resultat	10	78 762 030	145 658 314
		16 480 700	31 224 884
Ordinært resultat etter skattekostnad		62 281 330	114 433 430
Årsresultat		62 281 330	114 433 430



Organisasjonsnr: 981 363 019
ABBOTT DIAGNOSTICS TECHNOLOGIES AS

BALANSE

Beløp i: NOK **Note** **2023** **2022**

BALANSE - EIENDELER

Anleggsmidler

Immaterielle eiendeler

Varige driftsmidler

Maskiner og anlegg	5	188 903 860	178 896 058
Skip, rigger, fly og lignende	5	379 248	779 652
Sum varige driftsmidler		189 283 108	179 675 710

Finansielle anleggsmidler

Lån til foretak i samme konsern	12	919 776 965	2 512 219 785
Sum finansielle anleggsmidler		919 776 965	2 512 219 785

Sum anleggsmidler		1 109 060 073	2 691 895 495
--------------------------	--	----------------------	----------------------

Omløpsmidler

Varer

Varer	13	232 574 514	126 379 863
Sum varer		232 574 514	126 379 863

Fordringer

Kundefordringer	12	211 575	212 575
Andre fordringer	12,14	32 618 328	33 766 404
Utsatt skatt	10	8 908 643	
Konsernfordringer		201 889 135	237 630 341
Sum fordringer		243 627 681	271 609 320

Bankinnskudd, kontanter og lignende

Bankinnskudd, kontanter og lignende	14	10 860 295	9 737 480
Sum bankinnskudd, kontanter og lignende		10 860 295	9 737 480

Sum omløpsmidler		487 062 490	407 726 663
-------------------------	--	--------------------	--------------------

SUM EIENDELER		1 596 122 563	3 099 622 158
----------------------	--	----------------------	----------------------

BALANSE - EGENKAPITAL OG GJELD

Egenkapital

Innskutt egenkapital

Aksjekapital	11	2 000 000	2 000 000
Beholdning av egne aksjer	11	1 200 608 665	1 840 095 087



Sum innskutt egenkapital		1 202 608 665	1 842 095 087
Opptjent egenkapital			
Annen egenkapital		62 281 331	521 423 333
Sum opptjent egenkapital		62 281 331	521 423 333
Sum egenkapital		1 264 889 996	2 363 518 420
Gjeld			
Langsiktig gjeld			
Utsatt skatt	10	0	314 888 302
Sum avsetninger for forpliktelser		0	314 888 302
Annen langsiktig gjeld			
Sum langsiktig gjeld		0	314 888 302
Kortsiktig gjeld			
Leverandørgjeld	12	217 788 477	203 036 698
Betalbar skatt	10	12 841 560	113 354 403
Skyldige offentlige avgifter		20 129 503	16 906 168
Annen kortsiktig gjeld	12	80 473 027	87 918 167
Sum kortsiktig gjeld		331 232 567	421 215 436
Sum gjeld		331 232 567	736 103 738
SUM EGENKAPITAL OG GJELD		1 596 122 563	3 099 622 158



Organisasjonsnr: 981 363 019
ABBOTT DIAGNOSTICS TECHNOLOGIES AS

NOTEOPPLYSNINGER - SELSKAP - alle poster oppgitt i hele tall

Note
1

Regnskapsprinsipper

The annual accounts have been prepared in compliance with the Account Act and accounting principles generally accepted in Norway. It coincide to Norwegian accounting standards. Upon application, the company has been granted an exemption from the consolidated accounting obligation for parent companies in subgroups. Note

Note
3

Antall årsverk i regnskapsåret
302.00

Note
3

Spesifisering av resultatregnskapet

Lønnskostnader

<u>Lønn</u>	<u>Årets</u>	<u>Fjorårets</u>
	215945000.00	177703000.00
<u>Folketrygdavgift</u>	<u>Årets</u>	<u>Fjorårets</u>
	33636000.00	27063000.00
<u>Pensjonskostnader</u>	<u>Årets</u>	<u>Fjorårets</u>
	10517000.00	11073000.00
<u>Andre ytelser</u>	<u>Årets</u>	<u>Fjorårets</u>
	6071000.00	6071000.00
<u>Sum lønnskostnader</u>	<u>Årets</u>	<u>Fjorårets</u>
	267354000.00	221910000.00

Mer om årsverk og lønn

Included in cost of goods 2023: - 97 405 000. Total = 169 949 000 2022: - 74 696 000. Total = 147 214 000

Note

Ekstraordinære inntekter og kostnader



<u>Sum</u>	<u>Beløp</u>
<u>Balanseført verdi 31.12.</u>	<u>Varige driftsmidler Immaterielle eiend.</u>

Konsernregnskap

Morselskapet sitt navn

Forretningskontor for morselskapet

Begrunnelse for at datterselskap er utelatt fra konsolideringen

<u>Samlet beløp - tilknyttet selskap</u>	<u>Årets</u>	<u>Fjorårets</u>
<u>Samlet beløp - foretak i samme konsern</u>	<u>Årets</u>	<u>Fjorårets</u>
<u>Samlet beløp - foretak i samme konsern</u>	<u>Årets</u>	<u>Fjorårets</u>
<u>Samlet beløp - felles kontrollert virksomhet</u>	<u>Årets</u>	<u>Fjorårets</u>

<u>Pantstillelse</u>	<u>Beløp</u>
----------------------	--------------

Note
11

<u>Beholdning av egne aksjer</u>	<u>Antall</u>	<u>Pålydende</u>	<u>Andel av aksjek.</u>
	2000.00	2000.00	100.00%

Erverv

Endringer i beholdning av aksjer i løpet av regnskapsåret

Avhendelse

Endringer i beholdning av aksjer i løpet av regnskapsåret

Samvirkeforetak

Vedtektsbestemmelser/årsmøtevedtak/forslag til vedtak om medlemskapskonti

Mer om aksjer

Abbott Laboratories Inc prepares consolidated financial statements where Abbott Diagnostics Technologies As is included. Consolidated financial



statements can be provided by Abbott Laboratories with the address: Abbott
Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064-3500 USA



Skatteetaten

Vår dato
18.07.2022

Din/Deres dato

Saksbehandler
Robin Ingebrigtsen

800 80 000
Skatteetaten.no

Din/Deres referanse

Telefon
99778267

Org.nr
974761076

Vår referanse
2022/5641181

Postadresse
Postboks 9200 Grønland
0134 OSLO

ABBOTT DIAGNOSTICS TECHNOLOGIES AS
Postboks 6863 Rodeløkka
0504 OSLO

Dispensasjon fra kravet om å utarbeide årsregnskap og årsberetning på norsk

Vi viser til Abbott Diagnostics Technologies AS (org.nr. 981 363 019) sin søknad om dispensasjon fra kravet om å utarbeide årsregnskap og årsberetning på norsk.

Skattekontoret gir på bakgrunn av en konkret helhetsvurdering selskapet dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk, jf. regnskapsloven § 3-4 tredje ledd. Dispensasjonen forutsetter at engelsk språk benyttes i stedet ved utarbeidelsen, og at øvrige opplysninger som vedtaket baserer seg på, heller ikke endres vesentlig.

Kopi av dette brevet må sendes Regnskapsregisteret i Brønnøysund sammen med årsregnskapet. Det påligger den regnskapspliktige å dokumentere ved dette brev at tillatelsen er gitt.

Bakgrunn

Fra søknaden siteres:

Abbott Diagnostics Technologies AS sender herved søknad om å levere årsregnskap og årsberetning på engelsk.

Abbott Diagnostics Technologies AS er et selskap i Abbott Laboratories konsernet og er 100 % eid av Axis Shield AS, som igjen eies 100% av Axis Shield Ltd, som har forretningsadresse i Storbritannia.

Dette er et internasjonalt konsern, hvor den ultimate eier er Abbott Laboratories Inc som er børsnotert og har forretningsadresse i USA.

Abbott Diagnostics Technologies AS sin virksomhet består av å levere produkter og tjenester til helsesektoren internasjonalt. Selskapet er en del av et internasjonalt konsern der finansiell informasjon rapporteres gjennom flere selskapsledd. Dette gjør at kommunikasjon, inkludert finansiell informasjon, for det alt vesentlige skjer på engelsk.

Administrerende direktør er amerikansk statsborger og er dessuten et av to styremedlemmer i



selskapet. Det er derfor et stort behov for at årsregnskap og årsberetning presenteres på engelsk. Det bes på denne bakgrunn om fritak fra å levere årsregnskap og årsberetning på norsk og at årsregnskap og årsberetning kan leveres på engelsk.

Skattekontorets vurdering

Etter regnskapsloven § 3-4 tredje ledd skal "årsregnskapet og årsberetningen ... være på norsk. Departementet kan ved ... enkeltvedtak bestemme at årsregnskapet og/eller årsberetningen kan være på et annet språk."

I Ot. prp. nr. 42 (1997-1998) Om lov om årsregnskap mv., er det uttalt følgende om regnskapslovens formål, jf. pkt. 1.1:

Regjeringen har som siktemål at regnskapsloven skal bidra til informative regnskaper for ulike grupper av regnskapsbrukere. Regnskapsbrukerne er dels investorer og kreditorer som tilfører kapital til foretakene, og dels andre grupper som har interesse av å vite hvordan foretaket drives, f.eks. de ansatte og lokalsamfunnet. Informasjonen til kapitalmarkedet skal gi grunnlag for riktig prising av finansielle objekter. Riktig prisdannelse på aksjer er en forutsetning for at ressursbruken i samfunnsøkonomien skal bli best mulig. Gode regnskaper vil også gjøre det vanskeligere for markedsdeltakere å ta ut spekulasjonsgevinster med basis i skjevt fordelt informasjon.

Det fremgår således at et av hovedformålene med regnskapsloven er å bidra til "informative regnskaper for ulike grupper av regnskapsbrukere". Regnskapsbrukere vil omfatte, jf. uttalelsen i proposisjonen, blant andre investorer, kreditorer, ansatte, kunder og lokalsamfunnet.

Det er etter skattekontorets vurdering derfor avgjørende ved vurdering av om dispensasjon fra kravet til å utarbeide årsregnskap og/eller årsberetning på norsk kan gis, at det ikke foreligger mulige brukere av regnskapsinformasjon som blir vesentlig berørt negativt ved en eventuell dispensasjon.

Som nevnt ovenfor er det særlig hensynet til brukerne av regnskapsinformasjon som skal vurderes ved en dispensasjonssøknad. I dette tilfellet er det opplyst at kommunikasjon med de fleste av kunder og leverandører skjer på engelsk. Selskapets eiere er engelskspråklige og vil ikke ha mulighet for å forstå årsregnskap og årsberetning på norsk. Skattekontoret finner at disse forholdene samlet tilsier at dispensasjon fra kravet om å utarbeide årsregnskap og årsberetning på norsk kan gis.

Vennligst oppgi vår referanse ved henvendelse i saken.



Med hilsen

Magrit Kilen Støebner
underdirektør
Innsats, storbedrift
Skatteetaten

Robin Ingebrigtsen

Dokumentet er elektronisk godkjent og har derfor ikke håndskrevne signaturer.



**Annual accounts 2023
for
Abbott Diagnostics Technologies AS**



Abbott Diagnostics Technologies AS

Annual Report 2023

OVERVIEW OF THE BUSINESS

The company conducts research and development, production and distribution of in vitro diagnostic products. The company's products are sold to doctors' offices and hospital laboratories in more than 100 countries.

In 2023, the Oslo manufacturing site serviced markets around the world. Key markets included Norway, United States, Europe, China, Mexico, India, South Korea, Indonesia and Japan.

Tests available on the Afinion instrument include CRP, HbA1c, ACR and Lipid panel.

Four (4) fully automated production lines for the Afinion tests are in operation. The company is continuously working to improve quality, cost and efficiency.

Tests available on the NycoCard™ platform include CRP and HbA1c.

RESEARCH AND DEVELOPMENT

The company's Research and Development (R&D) department conducts specific research and development projects with the goal of developing instrumentation and new in vitro diagnostic analysis products for the global Point-of-Care market. The R&D department also supports the group's other companies with research projects in the early stages.

The following main R&D activities were the focus of 2023:

- Development of a second generation analysis product for measuring lipids on Afinion ("Afinion Lipid Panel") with a goal to obtain CLIA-waiver approval in the USA
- Development of a second generation analysis product for measuring ACR (albumin-creatinine ratio) on Afinion with goal to obtain CLIA waiver approval in the USA. ACR is, together with HbA1c, essential in the follow-up of patients with diabetes.
- Development of new tests for Afinion
- Change of raw material in on-market products

CONTINUING OPERATION

In accordance with the Accounting Act §3-3a, it is confirmed that the preconditions for continued operations are present. The assumption is based on profit forecasts for 2024 and as well the company's long-term strategic forecasts for the years ahead. The company is in a sound financial position.

HEALTH · ENVIRONMENTAL · SAFETY

In 2023, the company has ensured systematic EHS work at all levels in accordance with Norwegian law and Abbott Group requirements. Common EHS policy, goals and guidelines have been established. The EHS activities are an integrated part of the company's operating system, as well as daily work in production, project, and product. Activities for 2023 were carried out as planned.

Sickness absence for 2023 was 6,2%, an decrease from 2022 when sickness absence was 7,8%.



Abbott Diagnostics Technologies AS

Annual Report 2023

The company collaborates with internal and external occupational health services to carry out preventive work, and to prevent or reduce stress and other illness. The company implements continuous measures to assess performance and take corrective actions when necessary.

There have been 3 work-related injuries with absence registered in 2023. None where significant injuries.

Pollution to the external environment is monitored has been reduced through relevant action plans.

The company has contingency plans and an industrial protection organization.

EQUALITY

The company's goal is to be a workplace where there is fully equality between women and men. It is desirable to have a balance between women and men in all functions and departments in Abbott Diagnostics Technologies AS. Out of company's 305 employees, 128 were women and 177 men.

The company's management has good representation of both sexes, 3 women and 3 men.

The company has a good balance within all age groups that take care of a balanced work environment and competence distribution.

NFI REPORTING

Diversity is ingrained at Abbott. As a global healthcare leader, diversity is not just a moral virtue, it is a business necessity. We believe advancing diversity is critical. Diversity fuels creativity that drives innovation. Innovation produces life-changing technology that allows Abbott to serve its purpose -- helping people live healthier, fuller lives.

Abbott examined risks of gender discrimination through assessment of pay, benefit programs, policies, and routines. Employees who joined during the reporting year, are assessed as if their base pay was paid the entire year. Using annualized salaries is avoiding suggestions of unequal pay solely caused by the hiring date. A review of all benefit programs and policies was part of this assessment, since Abbott deploys no different policies for sub-groups no risk was identified.

The job categories that are used in this report, are defined based on job grade of the jobs. Abbott utilizes a points-based grading model using 3 factors: Know How, Accountability and Problem solving to assign roles to grades. The grade has been focused on the role and not on the individual or individuals who hold such position at present.

For 2023, Abbott has achieved a gender balance of employees. 42% were women and 58% were men.

During this assessment no risks for discrimination are identified. To continue this state, we will keep reinforcing our focus on avoiding discrimination, of all kind, in our policies, programs, and practices to make sure we deliver on our commitments to our employees and to the communities where they live and work.



Abbott Diagnostics Technologies AS

Annual Report 2023

INSURANCE COVERAGE

The board of directors and general manager are indemnified by the company for the responsibilities they perform on the company behalf up to a limit of US\$10 million via Directors & Officers Liability insurance policy held with Zurich UK Insurances.

FUTURE DEVELOPMENT

The company sees exciting growth opportunities with today's products, mainly related to the Afinion platform. Throughout 2023, significant resources have also been invested in projects related to the further development of the Afinion platform and manufacturing capacity.

Afinion 2 continues Abbott's work in diabetes treatment by providing patients with information about their health while they are at the appointment, which allows them to have a timely discussion with their doctor. The global increase in diabetes provides increased opportunities for our products, and we offer a panel of tests for follow-up of these patients. Afinion™ HbA1c Dx, the first and only patient-centered test approved for use in the diagnosis of diabetes and prediabetes in the United States, was launched in June 2019.

Increased focus on antibiotic resistance means that the company also expects increased demand for Afinion™ CRP.

Abbott Diagnostics Technologies AS is well prepared for further growth.

FINANCIAL RISK

The company's financial risk is primarily related to currency fluctuations. Of total operating revenues, 87% is in foreign currency.

The group has an active currency hedging policy and makes ongoing assessments of exposure. The company actively seeks to place costs in the same currency as the income.

The company's credit risk is considered limited as the company has a customer base that has historically shown a very good ability to pay.

PROFIT, INVESTMENTS, FINANCING AND LIQUIDITY

Turnover increased from NOK 1.051 million in 2022 to NOK 1.380 million in 2023. Profit before tax was NOK 78.8 million. Profit in 2023 was characterized by higher sale to other Abbott affiliates.

The company's liquidity as of 31.12.2023 was NOK 10,9 million. The company is part of the group's cash pooling account scheme with other Abbott companies in Norway. The company's financial position is good.

The total capital as of 31.12.2023 NOK 1.594,6 million, which is an decrease of NOK 1.505 million as of 31.12.2022 due to group contribution of NOK 1.488 million. Equity as NOK 1.264,9 million.



Abbott Diagnostics Technologies AS

Annual Report 2023


Abbott Diagnostics Technologies is required to do Transparency Act reporting and the report has been published on <https://www.abbott.com>.


ANNUAL RESULT AND ALLOCATION OF EARNINGS

The board proposes the following allocation of the company's profits:

Transferred to retained earnings NOK 62.281.331, -

Oslo, 27. June 2024


Oddvar Vanberg
Chairman


Todd Thessen
CEO/Board Member



Abbott Diagnostics Technologies AS

Income Statement

for the period 1 January to 31 December

OPERATING INCOME AND OPERATING EXPENSES	Note	2023	2022
Operating income			
Sales revenue	1	1 380 147 873	1 050 628 960
Other revenue	2	0	169 260
Total operating income		1 380 147 873	1 050 798 220
Operating expenses			
Cost of goods sold		505 877 210	397 344 558
Employee benefits expense	3, 4	169 949 276	147 214 024
Depreciation	5, 6, 7	32 889 022	34 082 946
Operating expenses	3, 6	677 936 496	384 934 022
Total operating expenses		1 386 652 003	963 575 550
OPERATING PROFIT		(6 504 130)	87 222 670
FINANCIAL INCOME AND EXPENSES			
Financial income			
Interest income from group companies		88 569 102	53 062 449
Other interest income		437 124	850 176
Other financial income	8	44 669 116	46 036 231
Net financial items		133 675 342	99 948 856
Financial expenses			
Interest expense to group companies		248 400	109 388
Other interest expenses		132 549	38 733
Other financial expenses	9	48 028 232	41 365 091
Net financial expenses		48 409 181	41 513 212
NET FINANCIAL ITEMS		85 266 161	58 435 645
PROFIT BEFORE EXTRAORDINARY ITEMS		78 762 031	145 658 315
PROFIT BEFORE TAX		78 762 031	145 658 315
Taxes	10	16 480 700	31 224 884
NET PROFIT OF THE YEAR		62 281 331	114 433 431
TRANSFERS AND ALLOCATIONS			
To equity	11	62 281 331	114 433 431
TOTAL		62 281 331	114 433 431



Abbott Diagnostics Technologies AS

Balance sheet as at 31. December

ASSETS	Note	2023	2022
Non-current assets			
Intangible assets			
Tangible assets			
Machinery and equipment	5	188 903 860	178 896 058
Fixture and furnitures		379 248	779 652
Total fixed assets		189 283 108	179 675 711
Non-current financial assets			
Loan to group companies	12	919 776 965	2 512 219 785
Total non-current financial assets		919 776 965	2 512 219 785
Total non-current assets		1 109 060 072	2 691 895 496
Current assets			
Inventory	13	232 574 514	126 379 863
Receivables			
Accounts receivables	12	211 575	212 575
Accounts receivables intercompany	12, 14	144 289 551	154 940 109
Other short-term receivables	12	32 618 328	33 766 404
Other intercompany receivables		57 599 584	82 690 232
Deferred tax assets	10	8 908 643	0
Total receivables		243 627 681	271 609 319
Cash and cash equivalents	14	10 860 295	9 737 480
Total current assets		487 062 490	407 726 662
Total assets		1 596 122 562	3 099 622 158





Abbott Diagnostics Technologies AS

Balance sheet as at 31. December

EQUITY AND LIABILITIES	Note	2023	2022
Equity			
Paid-in capital			
Share capital	11	2 000 000	2 000 000
Share premium reserve	11	1 200 608 665	1 840 095 087
Total paid-in capital		1 202 608 665	1 842 095 087
Earned capital			
Retained earnings		62 281 331	521 423 333
Total equity		62 281 331	521 423 333
Total capital	11	1 264 889 996	2 363 518 420
Liabilities			
Non-current liabilities			
Deferred tax liability	10	0	314 888 302
Total provisions		0	314 888 302
Current liabilities			
Account payables	12	217 788 477	203 036 698
Company income tax payable	10	12 841 560	113 354 403
Public duties payable		20 129 503	16 906 168
Other current liabilities	12	80 473 027	87 918 167
Total current liabilities		331 232 567	421 215 436
Total liabilities		331 232 567	736 103 738
Total equity and liabilities		1 596 122 562	3 099 622 158

The board of Abbott Diagnostics Technologies AS


Oddvar Arne Vanberg
Chairman of the Board


Fedd-Eric Thessen
CEO / Board Member



Abbott Diagnostics Technologies AS

Cash flow statement

	Note	2023	2022
Cash flows from operating activities			
Profit before tax		78 762 031	145 658 315
Taxation paid		-113 354 403	342 579 000
Depreciation		32 889 022	34 082 946
Loss on disposal fixed assets		0	367
Changes inventory, receivables and payables		-80 791 314	-37 329 000
Change in other current assets/liabilities		-3 073 729	29 652 000
Net cash flows from operating activities		-85 568 393	514 643 629
Cash flow from investment activities			
Investments in fixed assets		-42 496 419	-35 316 000
Changes loan group companies		104 096 980	-448 671 000
Net cash flows from investment activities		61 600 561	-483 987 000
Cash flows from financing activities			
Changes in receivable intercompany		0	0
Changes in cash pool		25 090 647	-28 086 000
Net cash flows from financing activities		25 090 647	-28 086 000
Net change in cash and cash equivalents		1 122 815	2 570 629
Cash and cash equivalents at the start of the period		9 737 480	7 166 484
Cash and cash equivalents at the end of the period		10 860 295	9 737 480



Accounting policies

Basic Policies

The annual accounts have been prepared in compliance with the Accounting Act and accounting principles generally accepted in Norway. It coincide to Norwegian accounting standards.

Upon application, the company has been granted an exemption from the consolidated accounting obligation for parent companies in subgroups.

Consolidated financial statements are prepared by Alere Inc.

Subsidiary / associated company

Subsidiaries are valued according to the cost method in the company accounts. The investment is valued at acquisition cost for the shares unless write-down has been necessary. Impairment has been made at fair value when impairment is due to reasons that cannot be assumed to be temporary, and this must be considered necessary in accordance with generally accepted accounting principles. Impairment losses are reversed when the basis for impairment is no longer present

Revenue recognition

Revenue recognition from the sale of goods takes place at the time of delivery. Royalty in connection with the sale of goods is recognized as income when this has been earned in accordance with reported sales to the end user.

When recognizing income in foreign currency, the exchange rate is used at the time of posting.

Research, development and patent costs

Own research and development costs and costs for registration and maintenance of associated patents are expensed.

Classification and assessment of balance sheet items

Current assets and current liabilities include items that fall due for payment within one year after the balance sheet date, as well as items related to the product cycle. Other items are classified as fixed assets/long-term debt.

Current assets are valued at the lower of acquisition cost and fair value. Current liabilities are capitalized at the nominal amount at the time of establishment.

Fixed assets are valued at acquisition cost, but are written down to fair value if the impairment is not expected to be temporary. Long-term debt is capitalized at the nominal amount at the time of establishment.

Receivables

Accounts receivable and other receivables are entered in the balance sheet at par value after deduction of provisions for expected losses. Accruals for losses are made on the basis of an individual assessment of the individual receivable.

Currency

Monetary items, receivables and liabilities in foreign currency are valued at the exchange rate at the end of the financial year.

The effect of changes is included in the income statement.

Fixed assets

Property, plant and equipment are capitalized and depreciated over the life of the fixed asset if they have a useful life of more than three years and a cost price that exceeds NOK 15,000.

Leasing

A distinction is made between financial and operational leasing after a specific assessment of the individual agreement. By financial leasing is meant agreements where the tenant takes over most of the benefits and risks associated with owning the fixed asset. Existing leasing agreements are considered to be operational, which means that leasing rent is expensed on an ongoing basis.

Intangible assets

Purchased research and development projects, patents, trademarks and goodwill are capitalized. Patents are depreciated over the patent's validity period. Other intangible assets are depreciated over their estimated economic life, provided that the asset can be valued independently.

**Inventory**

Inventory is valued at acquisition cost or manufacturing cost and deducted for obsolescence.

Bank deposit

The group's liquidity is organized in a group account scheme. This means that the subsidiaries' cash holdings are formally receivables from the parent company, and that all group companies are jointly and severally liable for the moves the group has made.

Tax

The tax expense in the income statement includes both the tax payable for the period and the change in deferred tax. Deferred tax is calculated at 22% on the basis of the temporary differences that exist between accounting and tax values, as well as tax losses carried forward at the end of the financial year. Tax-increasing and tax-reducing temporary differences that reverse or can reverse in the same period are offset and netted. Recognition of deferred tax assets is recognized when it is overwhelmingly probable that tax-reducing temporary differences can be utilized through income in future years.

Cash flow statement

Liquidity is defined as the sum of cash and bank deposits. The cash flow statement has been prepared according to the indirect method.



Figures given in thousands

Note 1 - Sales revenue

Geografic breakdown	2023	2022
Europe	446 235	316 451
USA	692 452	522 067
Other countries	238 269	217 226
IC margin adjustment	3 192	-5 115
TOTAL	1 380 148	1 050 629

Note 2 - Other operational income

	2023	2022
Royalties	0	169
TOTAL	0	169

Note 3 - Employee benefits

Salary costs

	2023	2022
Salaries	215 945	177 703
Employment tax	33 636	27 063
Pension expenses	6 804	8 020
Expenses related to AFP	3 713	3 053
Other remuneration	7 256	6 071
Reclassification to COGS	-97 405	-74 696
TOTAL	169 949	147 214

There was 302 employees per 31.12.2023

Benefits to senior executives	CEO	Board members
Salaries	4 296	0

There is no special remuneration agreed for the CEO or the board in case of resignation or change in employment. No special remuneration such as bonuses and provisions agreed.

Audit

Fees for statutory audit in 2023 have been expensed with NOK 529 069.
In addition tax services billed of NOK 84 000.



Figures given in thousands

Note 4 - Pension obligations

Pension costs and pension obligations

The company is obliged to have an occupational pension scheme in accordance with the Act on Mandatory Occupational Pensions, and the pension scheme meets the requirements of this Act.

The company has in 2023 contribution-based pension scheme.

The defined contribution pension comprises 302 employees in 2023. Premium paid for the period 01.01.2023 - 31.12.2023 amounts to NOK 6 803 799.

The company has a contractual early retirement scheme (AFP). The new AFP scheme, which applies from 1 January 2011, is to be regarded as a defined benefit plan, but is accounted for as a defined contribution scheme until reliable and sufficient information is available so that the group can account for its proportionate share of pension costs, pension obligations and pension assets. arrangement. The company's liabilities are thus not capitalized as debt.



Figures given in thousands

Note 5 - Tangible assets

	Assets under construction	Machines/equipment	Investments rented building	Total
Cost price 01.01.2023	39 952	574 944	66 826	681 721
Additions	41 356	2 280	161	43 797
Transfers	-25 937	25 937	0	0
Cost price 31.12.2023	55 371	603 161	66 987	725 519
Accumulated depreciation 01.01	0	439 319	62 916	502 235
Accumulated depreciation 31.12	0	472 207	64 029	536 236
Carrying amount 31.12.2023	55 371	130 954	2 958	189 283
Depreciation for the year	0	31 776	1 113	32 889

The company uses straight-line depreciation for all intangible assets and property, plant and equipment. The economic life of the fixed assets is calculated at:

Investments in rented buildings	10 years
Machines and inventory	3-15 years
Trademarks	5 years
Patents	12 years
Goodwill	20 years
Software/other intangible assets	10 years

The discounted excess return for the acquired businesses is expected to exceed the book values at any given time.

Information on leases/operating leases (annual rent)

	2023	2022	Remaining duration
Buildings	16 014	18 986	5 years
Machines/equipment	292	382	1-5 years
Total	16 306	19 368	



Figures given in thousands

Note 6 - Licences and patents

	Patents	Trademarks	Software/ other intangible	TOTAL
Acquisition cost per. 01.01.2023	128 000	21 137	97 746	246 883
Disposal of intangible assets	-128 000	-21 137	-97 746	-246 883
Acquisition cost 31.12.2023	0	0	0	0
Carrying amount 31.12.2023	0	0	0	0
Ordinary depreciation for the year	0	0	0	0

The company conducts research and development of in vitro diagnostic products. It is expected that earnings will cover expenses incurred.

Net expenses for research and development in 2023 of NOK 46.259.986,-, including government grant for 2023 of NOK 3.892.726.

Estimated government grant for 2023 of NOK 1.292.895 is not included in 2023 accounts.



Figures given in thousands

Note 7 - Goodwill

	Nycomed	Shanghai Upper Biotech	Total
Cost price 01.01.2023	37 229	1 819	39 048
Additions	0	0	0
Cost price 31.12.2023	37 229	1 819	39 048
Acc. depreciation and write-downs 01.01.2023	37 229	1 819	39 048
Carrying amount 31.12.2023	0	0	0
Ordinary depreciation for the year	0	0	0

Note 8 - Other financial revenue

	2023	2022
Foreign exchange gains	44 669	46 036
TOTAL	44 669	46 036

Note 9 - Other financial cost

	2023	2022
Foreign exchange loss	48 028	41 365
Sum	48 028	41 365



Figures given in thousands

Note 10 - Tax

	2023	2022
Allocation of tax expense		
Tax payable	340 278	113 354
Change in deferred tax	-323 797	-82 130
Total tax expense	16 481	31 225
Calculation of the tax base for the year	2023	2022
Profit before tax	78 762	145 658
Permanent differences	-3 850	-3 727
Changes in temporary differences	1 471 804	373 316
Group contribution	-1 488 346	0
The year's tax base	58 371	515 247
Temporary differences:	2023	2022
Account receivables	0	-2 123
Inventory	-8 303	-18 990
Tangible assets	-19 961	-21 017
Provision	-12 230	-14 905
Profit and loss account	0	1 488 346
Total	-40 494	1 431 310
Total	-40 494	1 431 310
Deferred tax (assets) 22 %	-8 909	314 888
Explanation of why the tax charge for the year is not to 22 % of net result before tax:	2023	2022
22 % tax on the result before tax	17 328	32 045
Permanent differences 22 %	-847	-820
Calculated tax charge	16 481	31 225
Effective tax rate	20,9 %	21,4 %



Figures given in thousands

Note 11 - Equity

	Share capital	Share premium	Retained earnings	Total
Equity 01.01.2023	2 000	1 840 095	521 423	2 363 518
Group contribution		-639 487	-521 423	-1 160 910
Profit of the year			62 281	62 281
Equity 31.12.2023	2 000	1 200 608	62 281	1 264 890



Figures given in thousands

Note 12 - Intercompany loan

	2023	2022
Receivables		
Intercompany accounts	144 290	154 940
Intercompany long term-receivables	919 777	2 512 220
TOTAL	1 064 067	2 667 160
Liabilities		
Intercompany accounts payable	131 801	125 545
Other intercompany short-term debt	-57 594	-81 747
TOTAL	74 208	43 797

Receivables maturing later than one year

	2023	2022
Intercompany long-term receivables	919 777	2 512 220

Debt maturing later than 5 years

	2023	2022
Long-term debt	0	0



Figures given in thousands

Note 13 - Inventory

Inventory	2023	2022
Raw materials	159 424	83 971
Semi finished goods	50 372	35 345
Finished goods	22 779	7 063
TOTAL INVENTORY	232 575	126 380

Inventory value is per 31.12.2023 valued at acquisition cost or manufacturing cost.

Note 14 - Bank deposits

Of cash and cash equivalents, the following are:

	2023	2022
Restricted bank deposit	10 860	9 737

The company is a part of Abbott Laboratories group cash pool. This means that all participating companies' withdrawals and deposits are netted against each other and the credit granted is calculated against the netted balance. All participants are jointly responsible for the groups liabilities to the bank, this includes credit limit, interests and fees. Ansvarret is limited according to The Norwegian Companies Act §1-4 and §8-7.

Per 31.12.2023 Abbott Diagnostics Technologies AS has NOK 55 887 982 in the Group cash pool. This is included in the Receivables intercompany amount.



Figures given in thousands

Note 15 - Share capital and shareholder information

Development in the company's own shares	Number	Face value per share	Booked value
Ordinary shares pr. 31.12.2023	1 000	2 000	2 000 000

Overview of the shareholders per 31.12.2023

	Number
Axis-Shield AS	1 000

Abbott Laboratories Inc prepares consolidated financial statements where Abbott Diagnostics Technologies AS is included.

Consolidated financial statements can be provided by Abbott Laboratories with the address:

Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-3500
USA

Note 16 - Financial Market Risk

Currency risk

Currency fluctuations represent both a direct and indirect financial risk for the company. The corporation has an active currency hedge policy, and makes ongoing assessment of exposure.



Figures given in thousands

Note 17 - Transactions with related parties

The balance sheet includes the following amounts as a result of transactions with associated companies:

	2023	2022
Sale of goods to:		
Intercompany	1 380 148	1 051 240
Sales of services to:		
Intercompany	0	1 364
Purchase of goods:		
Intercompany	423	278
Purchase of services:		
Intercompany	-23 206	-48 393
Financial items		
Interest income:		
Intercompany	88 569	53 062
Interest expense:		
Intercompany	248	109
Extraordinary income:		
Intercompany	0	0

Note 18 - Going concern/events after the balance sheet date

There are no significant events after the balance sheet date.



Statsautoriserte revisorer
Ernst & Young AS

Nygata 4, 1607 Fredrikstad

Foretaksregisteret: NO 976 389 387 MVA
Tlf: +47 24 00 24 00

www.ey.no
Medlemmer av Den norske Revisorforening

INDEPENDENT AUDITOR'S REPORT

To the Annual Shareholders' Meeting of Abbott Diagnostics Technologies AS

Opinion

We have audited the financial statements of Abbott Diagnostics Technologies AS (the Company), which comprise the balance sheet as at 31st December 2023, the income statement and statement of cash flows for the year then ended and notes to the financial statements, including a summary of significant accounting policies.

In our opinion the financial statements comply with applicable legal requirements and give a true and fair view of the financial position of the Company as at 31st December 2023 and its financial performance and cash flows for the year then ended in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Company in accordance with the requirements of the relevant laws and regulations in Norway and the International Ethics Standards Board for Accountants' *International Code of Ethics for Professional Accountants (including International Independence Standards)* (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

Other information consists of the information included in the annual report other than the financial statements and our auditor's report thereon. Management (the board of directors and the general manager) is responsible for the other information. Our opinion on the financial statements does not cover the other information, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information, and, in doing so, consider whether the board of directors' report contains the information required by legal requirements and whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information or that the information required by legal requirements is not included, we are required to report that fact.

We have nothing to report in this regard, and in our opinion, the board of directors' report is consistent with the financial statements and contains the information required by applicable legal requirements.

Responsibilities of management for the financial statements

Management is responsible for the preparation of the financial statements that give a true and fair view in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the



Building a better
working world

going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the board of directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Fredrikstad, 28th June, 2024
ERNST & YOUNG AS

The auditor's report is signed electronically

Terje Havn
State Authorised Public Accountant (Norway)

Independent auditor's report – Abbott Diagnostics Technologies AS 2023

A member firm of Ernst & Young Global Limited

Planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



PENNEO

Signaturene i dette dokumentet er juridisk bindende. Dokument signert med "Penneo" sikker digital signatur. De signerende porter sin identitet er registrert, og er listet nedenfor.

"Med min signatur bekrefter jeg alle dataer og innholdet i dette dokument."

Havn, Terje

Statsautorisert revisor

Serienummer: no_bankid:9578-5994-4-464108

IP: 178.232.xxx.xxx

2024-06-28 13:09:07 UTC



Penneo Dokumentnøkkel: TSVEB-H00CK-IUE5c-AD40A-JFWUJ-BN6TH

Dokumentet er signert digitalt, med **Penneo.com**. Alle digitale signatur-data i dokumentet er sikret og validert av den digitalmøskin-utregnede hash-verdien av det opprinnelige dokument. Dokumentet er låst og tids-stemplet med et sertifikat fra en betrodd tredjepart. All kryptografisk bevis er integrert i denne PDF, for fremtidig validering (hvis nødvendig).

Hvordan bekrefter at dette dokumentet er originalen?

Dokumentet er beskyttet av ett Adobe CDS sertifikat. Når du åpner dokumentet i

Adobe Reader, skal du kunne se at dokumentet er sertifisert av **Penneo e-signature service <penneo@penneo.com>**. Dette garanterer at innholdet i dokumentet ikke har blitt endret.

Det er lett å kontrollere de kryptografiske beviser som er lokalisert inne i dokumentet, med Penneo validator - <https://penneo.com/validator>